Valuation : Control Bionics Limited

Market Cap 31.5M 22.74M 19.55M 18.39M 16.79M 31.4M 2.15B 218M 84.29M 1.1B 85.38M 83.52M 3.51B P/E 2025
-1.3x
P/E 2026 -3.78x
Enterprise Value 29.96M 21.63M 18.6M 17.49M 15.97M 29.87M 2.05B 207M 80.18M 1.05B 81.22M 79.45M 3.34B EV / Sales 2025
1.4x
EV / Sales 2026 6.07x
Free-Float
73.44%
Yield 2025 *
-
Yield 2026 -
1 day+6.90%
1 week+1.64%
Current month+3.33%
1 month-7.46%
3 months-17.33%
6 months+10.71%
Current year+1.64%
1 week 0.06
Extreme 0.058
0.06
1 month 0.06
Extreme 0.056
0.07
Current year 0.05
Extreme 0.05
0.1
1 year 0.03
Extreme 0.032
0.1
3 years 0.03
Extreme 0.026
0.1
5 years 0.03
Extreme 0.026
0.73
10 years 0.03
Extreme 0.026
1.24
Manager TitleAgeSince
Chief Executive Officer - 2023-01-18
Director of Finance/CFO - 2024-05-12
Chief Tech/Sci/R&D Officer - 2013-12-31
Director TitleAgeSince
Chairman 66 2025-11-18
Director/Board Member - 2023-01-18
Director/Board Member - 2023-03-31
Change 5-day change 1-year change 3-year change Capi.($)
+6.90%+1.64%+77.14%-18.42% 22.74M
+0.94%-4.61%+20.77%-32.44% 16.82B
-3.03%+0.56%-36.25%+48.62% 1.61B
+0.29%-3.19%-51.29%-81.53% 958M
-1.07%-5.05%-24.16%+20.31% 915M
-0.05%+0.11%+58.88%-3.99% 780M
+0.09%-0.35%-32.75%-46.80% 672M
+0.45%+3.75%-35.06%-41.53% 622M
-17.81%-23.96%-47.76%-44.23% 511M
+0.10%-5.81%+84.74%+48.23% 415M
Average -1.32%-2.33%+1.43%-15.18% 2.33B
Weighted average by Cap. +0.08%-4.88%+10.04%-25.29%

Financials

2025 2026
Net sales 6.14M 4.44M 3.81M 3.59M 3.28M 6.13M 419M 42.54M 16.44M 215M 16.66M 16.29M 684M 4.77M 3.44M 2.96M 2.78M 2.54M 4.75M 325M 33M 12.75M 167M 12.92M 12.64M 531M
Net income -6.11M -4.41M -3.79M -3.57M -3.26M -6.09M -417M -42.29M -16.35M -214M -16.56M -16.2M -680M -7.27M -5.24M -4.51M -4.24M -3.87M -7.24M -496M -50.3M -19.44M -254M -19.69M -19.26M -809M
Net Debt -237K -171K -147K -139K -126K -236K -16.2M -1.64M -635K -8.29M -643K -629K -26.42M -1.54M -1.11M -953K -897K -819K -1.53M -105M -10.63M -4.11M -53.69M -4.16M -4.07M -171M
Logo Control Bionics Limited
Control Bionics Limited is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses, such as Motor Neurone Disease and Amyotrophic Lateral Sclerosis. Its products include Control Bionics Trilogy Systems, NeuroStrip, NeuroNode, Cosmos Connect and accessories. NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as electromyography output. This output is then sent wirelessly via NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse and the NeuroNode acts like a mouse button. It is commercializing its advancement in its technology, NeuroStrip. It is focused on neuromuscular rehabilitation and athletic optimization.
Employees
-
Date Price Change Volume
26-09-08 A$0.0620 +6.90% 214,999
26-09-07 A$0.0580 -1.69% 367,203
26-09-04 A$0.0590 -4.84% 110,001
26-09-03 A$0.0620 +6.90% 55,552
26-09-02 A$0.0580 -4.92% 334,879
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!